

1 **Rates of production and utilisation of lactate by microbial communities from the**  
2 **human colon**

3

4 Alvaro Belenguer<sup>1\*</sup>, Grietje Holtrop<sup>2</sup>, Sylvia H. Duncan<sup>1</sup>, Susan E. Anderson<sup>1</sup>, A.Graham  
5 Calder<sup>1</sup>, Harry J. Flint<sup>1</sup>, and Gerald E. Lobley<sup>1</sup>

6

7 <sup>1</sup>The Rowett Institute of Nutrition and Health, <sup>2</sup>Biomathematics and Statistics Scotland,  
8 Greenburn Road, Bucksburn, Aberdeen, AB21 9SB, UK

9

10

11

12 **Running title:** Lactate metabolism by colonic microbiota

13

14 \* **Correspondence: Present address:** Alvaro Belenguer, Instituto de Ganadería de  
15 Montaña (CSIC - Universidad de León), Finca Marzanas s/n, 24346 Grulleros, León,  
16 Spain. Tel.: +34 987 317156; fax: +34 987 317161; e-mail: A.Belenguer@eae.csic.es

17

18

19 **Keywords:** colonic bacteria, human health, lactate metabolism, stable isotope.

20

21     **Abstract**

22     Lactate metabolism was studied in mixed bacterial communities using single stage  
23     continuous flow fermentors inoculated with faecal slurries from four different volunteers  
24     and run for 6 days at pH 5.5 and 6.0, using carbohydrates, mainly starch, as substrates. A  
25     continuous infusion of [U-<sup>13</sup>C]starch and L-[3-<sup>13</sup>C]lactate was performed on day 5 and a  
26     bolus injection of L-[3-<sup>13</sup>C]lactate plus DL-lactate on day 6. Short chain fatty acids and  
27     lactate concentrations plus enrichments and numbers of lactate producing and utilizing  
28     bacteria on day 5 were measured. Faecal samples were also collected weekly over a 3-  
29     month period to inoculate 24h-batch culture incubations at pH 5.9 and 6.5 with  
30     carbohydrates alone or with 35 mmol L<sup>-1</sup> lactate. In the fermentors, potential lactate  
31     disposal rates were more than double formation rates, and lactate concentrations usually  
32     remained below detection. Lactate formation was greater ( $P < 0.05$ ) at the lower pH with a  
33     similar tendency for utilization. Up to 20% of butyrate production was derived from  
34     lactate. In batch cultures lactate was also efficiently used at both pH values, especially at  
35     6.5, although volunteer and temporal variability existed. Under healthy gut environmental  
36     conditions, bacterial lactate disposal seems to markedly exceed production.

37

## 38 **Introduction**

39 The metabolic activities of gut bacteria have a considerable influence in human health  
40 and disease (Guarner & Malagelada, 2003). Dietary carbohydrate substrates, including  
41 starch (Jacobasch *et al.*, 1999), that escape digestion by host enzymes may be fermented by  
42 microbes to short chain fatty acids (SCFA) in the colon. Acetate is the predominant  
43 product of such fermentation but may also be converted to butyrate by several bacterial  
44 species in the colon by the action of butyryl CoA: acetate CoA transferase (Pryde *et al.*,  
45 2002; Duncan *et al.*, 2004a; Louis *et al.*, 2004). Butyrate, which is not further metabolised  
46 by microbes in the colon (Belenguer *et al.*, 2008), is the preferred energy source for the  
47 colonocytes (Pryde *et al.*, 2002; Gill & Rowland., 2002) and may help ameliorate  
48 inflammation and prevent colorectal cancer (McIntyre *et al.*, 1993; Tazoe *et al.*, 2008;  
49 Hamer *et al.*, 2008; Louis & Flint, 2009).

50 Propionate is the other major fermentation product detected in the colon whilst lactate  
51 is an intermediate product usually found in low concentrations in faecal samples from  
52 healthy subjects ( $< 5 \text{ mmol L}^{-1}$ ) due to further microbial utilization and conversion to  
53 butyrate, propionate or acetate (Belenguer *et al.*, 2007). Lactate is a product of several  
54 bacterial groups, including bifidobacteria (Florent *et al.*, 1985) and certain anaerobes  
55 (Mcfarlane & Gibson, 1991; Duncan *et al.*, 2002). At low concentrations lactate is  
56 considered beneficial in the colon as the low pKa makes it inhibitory to pathogens. Lactate,  
57 however, may accumulate to high concentrations (up to  $90 \text{ mmol L}^{-1}$ ) in the colonic lumen  
58 of ulcerative colitis sufferers (Vernia *et al.*, 1988) with detrimental effects, including  
59 neurotoxic responses (Ewarschuk *et al.*, 2005).

60 Among the factors that affect the gut microbial ecosystem, pH impacts markedly on the  
61 composition and metabolism of the colonic microbiota (Walker *et al.*, 2005; Duncan *et al.*,  
62 2009). This is also the case for lactate metabolism and previous studies have shown that  
63 lactate production and utilization are maintained in balance by mixed human faecal

64 bacteria (Bourriaud *et al.*, 2005; Morrison *et al.*, 2006), within the normal physiological pH  
65 range (Belenguer *et al.*, 2007). At pH 5.2, however, lactate utilization was curtailed and  
66 this metabolite accumulated (Belenguer *et al.*, 2007). This may explain high lactate  
67 concentrations in severe colitis (Vernia *et al.*, 1988) where the colonic pH can approach  
68 that of the stomach (Fallingborg *et al.*, 1993). The contribution of various bacterial species  
69 to lactate utilization remains ill-defined, however, but several are known to convert lactate  
70 to propionate or butyrate (Duncan *et al.*, 2004b; Morrison *et al.*, 2006; Falony *et al.*, 2006).  
71 These include *Eubacterium hallii*, *Anaerostipes caccae* and an un-named species (Duncan  
72 *et al.*, 2004b) that are butyrate-producing bacteria and belong to the dominant core group  
73 of species in the human intestinal microbiota (Tap *et al.*, 2009; Walker *et al.*, 2010).

74

75 Maintenance of low amounts of lactate within the colon represents a balance between  
76 utilization and production and imbalances in either can cause lactate accumulation. The  
77 current study uses two approaches, long-term (6 days) continuous fermentors and short  
78 term (24h) batch cultures to estimate rates of lactate production and utilization and  
79 determine if these link to certain bacterial groups. The pH of the culture media was shown  
80 to modify rates of lactate metabolism and stable isotope approaches were used to allow  
81 quantification of flow from starches to lactate and to end-product metabolites.

82

## 83 **Material and methods**

### 84 **Collection of faecal samples**

85 These were provided by four adult volunteers (two male and two female), aged 32-62  
86 years and all consuming a Western style diet. The volunteers (referred to as donors A, B, C  
87 and D) did not take any antibiotics or drugs known to influence faecal microbiota for the  
88 last 6 months prior to the start of the studies.

89

## 90        **Continuous flow fermentor incubations**

91        Single-stage continuous fermentor systems were operated as described previously  
92        (Duncan *et al.*, 2003) using a medium based on that of Macfarlane *et al.* (1989) as  
93        modified by Walker *et al.* (2005). The carbon sources present in the mixed substrate  
94        medium were potato starch (0.5% weight in volume, w/v) in addition to xylan, pectin,  
95        amylopectin and arabinogalactan each at 0.06% (w/v). The total peptide concentrations  
96        (comprising equal amounts of casein hydrolysate and peptone water) were 0.2%. The  
97        fermentor growth medium was maintained under a stream of CO<sub>2</sub> with a flow rate of fresh  
98        medium equating to one pool per day, giving a dilution rate of 0.042 h<sup>-1</sup>. Prime doses of  
99        SCFA were added to give initial concentrations of approximately 35 mmol L<sup>-1</sup> acetate, 9  
100        mmol L<sup>-1</sup> propionate, 5 mmol L<sup>-1</sup> butyrate and 1 mmol L<sup>-1</sup> each of valerate, iso-valerate,  
101        and iso-butyrate, but were not included in the supplied medium. The pH was maintained at  
102        either 5.5 ± 0.1 (vessel 1) or 6.0 ± 0.1 (vessel 2). The temperature was maintained at 37°C  
103        using a thermal jacket. Faecal suspensions (20%) were prepared by suspending fresh faecal  
104        samples in 50 mmol L<sup>-1</sup> phosphate buffer (pH 6.5) containing 0.05% cysteine under O<sub>2</sub>-  
105        free CO<sub>2</sub> to give a faecal inoculum of 2% (w/v) in the vessel. Substrate (mixture of  
106        carbohydrates) was infused continuously, with potato soluble starch being supplied at  
107        approximately 16 and 22 mg h<sup>-1</sup> (which would be equivalent to approximately 92 and 124  
108        µmol glucose h<sup>-1</sup>) in vessels 1 and 2, respectively.

109        For the lactate metabolism studies a continuous infusion of [U-<sup>13</sup>C]starch (equivalent to  
110        7.35-8.83 and 10.95-17.00 µmol glucose h<sup>-1</sup> in vessels 1 and 2, respectively) and L-[3-  
111        <sup>13</sup>C]lactate (5.29-6.58 and 6.58-7.88 µmol h<sup>-1</sup> in vessels 1 and 2, respectively) was  
112        performed for 10 h on day 5, with a prime injection of [1-<sup>13</sup>C]acetate (184.2-384.8 and  
113        219.4-298.6 µmol in vessels 1 and 2, respectively), [1,2-<sup>13</sup>C]acetate (176.9-402.3 and  
114        195.7-296.4 µmol in vessels 1 and 2, respectively) and [1-<sup>13</sup>C]propionate (9.4-22.2 and  
115        7.6-21.7 µmol in vessels 1 and 2, respectively) given approximately 4 h after the start of

116 the infusion of labelled starch and lactate. The following day (day 6) both vessels received  
117 a bolus injection of L-[3-<sup>13</sup>C]lactate (approximately 23 and 28  $\mu\text{mol}$  in vessels 1 and 2,  
118 respectively) plus DL-lactate (approximately 230 and 275  $\mu\text{mol}$  in vessels 1 and 2,  
119 respectively).

120 Daily samples were taken from each vessel to monitor SCFA and lactate concentrations.  
121 On the infusion day (day 5) samples were taken every 30 min for the first 3 h of the  
122 infusion and hourly thereafter until 10 h to measure SCFA and lactate concentrations and  
123 metabolite <sup>13</sup>C enrichments. On the injection day (day 6) samples were taken at 30 min  
124 intervals from just before until 4 h after the bolus injection, with lactate concentrations and  
125 metabolite <sup>13</sup>C enrichments measured.

126

### 127 **Batch culture incubations**

128 Fresh faecal samples from the same four volunteers (A, B, C and D) were collected  
129 weekly at 12 occasions over a three month period. Slurries of this material were used for  
130 batch culture incubations with an anaerobic medium similar to that used for the continuous  
131 flow fermentor incubations, based on Macfarlane *et al.* (1989) as modified by Walker *et al.*  
132 (2005). The carbohydrate sources present in the mixed substrate medium were potato  
133 starch (0.14% w/v) in addition to xylan, pectin, amylopectin, and arabinogalactan each at  
134 0.015% (w/v). The total peptide concentrations (comprising equal amounts of casein  
135 hydrolysate and peptone water) were 0.2%. Samples were inoculated at two different pH  
136 values (mean  $\pm$  standard deviation  $5.9 \pm 0.2$  and  $6.5 \pm 0.2$ ) and with either a carbohydrate  
137 mixture alone or with DL-lactate (approximately 35  $\text{mmol L}^{-1}$  initial concentration) also  
138 present. SCFA were also added to the medium to give initial concentrations of  
139 approximately 33  $\text{mmol L}^{-1}$  acetate, 9  $\text{mmol L}^{-1}$  propionate, 5  $\text{mmol L}^{-1}$  butyrate and 1  
140  $\text{mmol L}^{-1}$  each of valerate, iso-valerate, and iso-butyrate. The fermentor medium was  
141 dispensed into Hungate tubes under a stream of  $\text{CO}_2$  (Miyazaki *et al.*, 1997) and heat

142 sterilised at 121 °C (15 min). After cooling, heat-labile vitamins were added and the  
143 medium was inoculated with the faecal slurry under CO<sub>2</sub> and incubated at 37 °C. Faecal  
144 slurries (20%) were prepared within 2 h of collection in anaerobic phosphate buffer saline  
145 to give a final concentration of approximately 0.2%. Tubes were inoculated in duplicate  
146 and samples were taken at 24 h to measure SCFA and lactate concentrations. Samples of  
147 uninoculated medium were also taken to measure initial concentrations and initial pH  
148 values.

149

### 150 **Quantification of bacteria in faecal and continuous fermentor samples by** 151 **fluorescent in situ hybridization analysis**

152 Samples were taken from faeces (0.5 g) and the fermentor incubations on day 5 (1 ml)  
153 for fluorescent in situ hybridization (FISH) analysis. Faecal samples were diluted with  
154 phosphate buffer (1:10), and all samples were fixed by mixing 1:3 in 4% (w/v)  
155 paraformaldehyde at 4°C for 16 h and stored at -20°C. FISH analysis was performed as  
156 described by Harmsen *et al.* (2002). Diluted cell suspensions were applied to gelatin-  
157 coated slides and the slides were hybridized overnight with the appropriate probes. 50 µl of  
158 Vectashield (Vector Laboratories, Burlingame, CA) was applied to each slide to prevent  
159 fading. Cells were counted automatically using image analysis software CellF (Olympus  
160 Soft Imaging Solutions GmbH, Germany) with an Olympus microscope, except when the  
161 number of cells was less than 10 per field of view, in which case the cells were counted  
162 manually. For each sample 30 microscopic fields were counted and the data averaged. All  
163 samples were assessed with the following probes: total bacteria (Eub338, Amann *et al.*,  
164 1990), *Bifidobacterium* spp. (Bif164, Langendijk *et al.*, 1995), as lactate-producing  
165 bacteria, and the *Eubacterium hallii* (Ehal1469, Harmsen *et al.*, 2002) and *Anaerostipes*  
166 *caccae* (Acac194, Hold *et al.*, 2002) groups, as potential lactate utilisers.

167

168        **Determination of concentrations and <sup>13</sup>C enrichments in short chain fatty acids**  
169        **and lactate**

170        Daily samples from the single-stage continuous fermentors were derivatised in duplicate  
171        for estimation of concentrations of SCFA and lactate by capillary gas chromatography  
172        (Richardson *et al.*, 1989). Similar analyses were performed for blank and 24h samples  
173        from the batch culture incubations to measure lactate concentrations. Samples from the  
174        fermentors on the infusion day (day 5) were analysed for lactate and SCFA concentrations  
175        and enrichments but only lactate concentrations and enrichments were determined in the  
176        samples collected during the injection day (day 6). For samples from both day 5 and 6  
177        concentrations were quantified by isotope dilution, while enrichments were measured by  
178        gas chromatography-mass spectrometry analysis of the *tert*-butyldimethylsilyl derivatives,  
179        as described previously (Duncan *et al.*, 2004a; Belenguer *et al.*, 2006). Analyses were  
180        under electron impact ionisation conditions; for acetate, the ions M<sup>+</sup>, M+1 and M+2 at  
181        mass/charge (m/z) 117, 118 and 119 were monitored; for butyrate, M<sup>+</sup>, M+1, M+2 and  
182        M+4 (i.e. m/z 145, 146, 147 and 149) were determined, the latter to quantify butyrate  
183        formation from two [1,2-<sup>13</sup>C] acetate molecules; for propionate, M<sup>+</sup>, M+1, M+2 and M+3  
184        (i.e. m/z 131, 132, 133 and 134) were measured; for lactate, M<sup>+</sup>, M+1, M+2 and M+3 ion  
185        fragments were analysed (m/z 261, 262, 263 and 264). For the concentration  
186        determinations appropriate corrections were applied for the enrichments of the samples.

187

188        **Metabolic activities of pure cultures of bacteria**

189        Based on data reported previously (Belenguer *et al.*, 2006) rates of conversion of 0.2%  
190        (w/v) starch substrate to lactate in batch cultures were calculated at pH 5.7 and 6.7 between  
191        4 and 8 h of incubation. Similarly the activity of *E. hallii* to utilise lactate was determined  
192        in the presence of 45 mmol L<sup>-1</sup> lactate at pH 5.7 and 6.7 between 8 and 24 h of incubation.



193 For both species, the number of bacteria in the respective incubations was determined by  
194 optical density ( $1 \text{ OD}_{600} = 10^9$  cells; Lech *et al.*, 1987).

195

### 196 **Kinetic modelling**

197 The model structure and fates of the various isotopes are shown in Fig. 1. Let  $q$ ,  $Q$ , and  
198  $E$  denote the labelled amount ( $\mu\text{mol}$ ), the total (labelled plus unlabelled) amount ( $\mu\text{mol}$ )  
199 and enrichment (0.01 molar % excess, MPE) of either acetate, butyrate, propionate, lactate,  
200 or starch, denoted by subscripts 'a', 'b', 'p', 'l' and 's', respectively. Let  $i$  denote the  
201 interval between any two times  $t_0$  and  $t_1$ , with  $t_1 > t_0$ , and let  $F(i)$  denote the flow of a  
202 metabolite (labelled plus unlabelled) during  $i$ .  $\text{Eff}(i)$  denotes the loss to the effluent during  
203 interval  $i$ , and  $E(i)$  denotes the average enrichment during  $i$ . Subscript 'in' refers to inflow  
204 (production) and subscript 'out' refers to use in further metabolic processes (e.g. acetate  
205 used to produce butyrate). For example,  $F_{a,\text{in}}$  refers to acetate production, while  $F_{a,\text{out}}$  stands  
206 for acetate outflow, etc. Flows to pool  $y$  from pool  $x$  are denoted by  $F_{yx}$ .  $Q$ ,  $q$ ,  $E$  and  $\text{Eff}$   
207 were measured, whilst the  $F_{yx}$ ,  $F_{\text{in}}$  and  $F_{\text{out}}$  were unknown.

208 Data are expressed in terms of two carbon ( $C_2$ ) units, to allow for 'molar equivalent'  
209 transfers. To achieve this, the concentration of butyrate is multiplied by 2 and the  
210 enrichment divided by 2. The enrichments of propionate and lactate, in terms of  $C_2$  units,  
211 are given as  $0.01 (\text{MPE}(M+2) + \text{MPE}(M+3))$ . The concentrations of acetate, propionate  
212 and lactate and their  $M+1$  enrichments are as measured directly.

213

214 *Infusion day (day 5):*

215 Calculations are based on time points during the continuous infusion of labelled starch  
216 and lactate between 4 and 10 h, after the prime doses of labelled acetate and propionate.  
217 Lactate formation ( $F_{l,\text{in}}$ ) and utilisation ( $F_{l,\text{out}}$ ) were obtained from the changes in labelled

218 (M+1) and total (labelled plus unlabelled) lactate as observed during the continuous  
 219 infusion of [3-<sup>13</sup>C]lactate:

$$220 \quad q_{l,m+1}(t_1) = q_{l,m+1}(t_0) + \text{Infusion}(i) - E_{l,m+1}(i) F_{l,out}(i) - E_{l,m+1}(i) \text{Eff}_l(i) \quad (1)$$

$$221 \quad Q_l(t_1) = Q_l(t_0) + \text{Infusion}(i) + F_{l,in}(i) - F_{l,out}(i) - \text{Eff}_l(i) \quad (2)$$

222

223 It was assumed that butyrate was formed ( $F_{b,in}$ ) via two pathways, either through the  
 224 extracellular acetate pool ( $F_{ba}$ ) or directly from lactate ( $F_{bl}$ ). First, from the changes in the  
 225 total butyrate concentration  $F_{b,in}$  was obtained:

$$226 \quad Q_b(t_1) = Q_b(t_0) + F_{b,in}(i) - \text{Eff}_b(i) \quad (3)$$

227 Then, changes in the M+1 enriched butyrate were modelled as

$$228 \quad q_{b,m+1}(t_1) = q_{b,m+1}(t_0) + E_{l,m+1}(i) F_{bl}(i) + E_{a,m+1}(i) F_{ba}(i) - E_{b,m+1}(i) \text{Eff}_b(i) \quad (4)$$

229 Writing  $F_{ba} = F_{b,in} - F_{bl}$  and substituting in equation (4) then provides  $F_{bl}$ , and  $F_{ba}$   
 230 follows.

231

232 The total production of propionate ( $F_{p,in}$ ) was obtained from

$$233 \quad Q_p(t_1) = Q_p(t_0) + F_{p,in}(i) - \text{Eff}_p(i) \quad (5)$$

234 where it was assumed that propionate has no further metabolic fates, i.e.  $F_{p,out} = 0$ .

235 Changes in labelled propionate derived from 3-<sup>13</sup>C-lactate were modelled as:

$$236 \quad q_{p,m+1}(t_1) = q_{p,m+1}(t_0) + E_{l,m+1}(i) F_{pl}(i) - E_{p,m+1}(i) \text{Eff}_p(i) \quad (6)$$

237 which then provided an estimate for  $F_{pl}$ .

238

239 The incorporation of lactate into acetate ( $F_{al}$ ) is obtained from assuming that lactate may  
 240 be utilised only to produce acetate, butyrate and propionate:  $F_{l,out} = F_{al} + F_{bl} + F_{pl}$ .

241 Furthermore, the M+1 acetate movements yield an estimate for  $F_{a,out}$ , based on:

$$242 \quad q_{a,m+1}(t_1) = q_{a,m+1}(t_0) + E_{l,m+1}(i) F_{al}(i) - E_{a,m+1}(i) F_{a,out}(i) - E_{a,m+1}(i) \text{Eff}_a(i) \quad (7)$$

243  $F_{a,in}$  follows from

244 
$$Q_a(t_1) = Q_a(t_0) + F_{a.in}(i) - F_{a.out}(i) - Eff_a(i) \quad (8)$$

245

246 Incorporation of starch into acetate ( $F_{as}$ ), lactate ( $F_{ls}$ ) and propionate ( $F_{ps}$ ) was obtained  
 247 from the changes in labelled metabolites that were produced from the infused [ $U-^{13}C$ ]  
 248 starch. For  $F_{ls}$ :

249 
$$q_{l.m+2}(t_1) = q_{l.m+2}(t_0) + E_s F_{ls}(i) - E_{l.m+2}(i) F_{l.out}(i) - E_{l.m+2}(i) Eff_l(i) \quad (9)$$

250 Here it is assumed that both M+2 and M+3 lactate were formed from [ $U-^{13}C$ ]starch (i.e.  
 251  $E_{l.m+2} = 0.01 MPE_{lactate}(M+2) + 0.01 MPE_{lactate}(M+3)$ ). Making similar assumptions for  
 252 propionate,  $F_{ps}$  follows from:

253 
$$q_{p.m+2}(t_1) = q_{p.m+2}(t_0) + E_{l.m+2}(i) F_{pl}(i) + E_s(i) F_{ps}(i) - E_{p.m+2}(i) Eff_p(i) \quad (10)$$

254 Incorporation of starch into acetate follows from:

255 
$$q_{a.m+2}(t_1) = q_{a.m+2}(t_0) + E_{l.m+2}(i) F_{al}(i) + E_s F_{as}(i) - E_{a.m+2}(i) F_{a.out}(i) - E_{a.m+2}(i) Eff_a(i) \quad (11)$$

256

257

258 *Bolus injection of labelled lactate (day 6):*

259 Except in the vessel at the lower pH (5.5) inoculated with a faecal suspension from  
 260 volunteer A, no lactate was detected so that lactate enrichments  $E_{l.m+1}$  and  $E_{l.m+2}$  could not  
 261 be determined. Estimates of lactate formation were based, instead, on samples collected  
 262 following the bolus injection of [ $3-^{13}C$ ]lactate on day 6. Lactate utilisation ( $F_{l.out}$ ) on day 6  
 263 was obtained from the changes in labelled (M+1) lactate (based on equation (1), with  
 264 ‘Infusion’ set equal to zero). This was then used to obtain  $F_{l.in}$ , based on changes in total  
 265 (labelled plus unlabelled) lactate (equation (2), with ‘Infusion’ set to zero). The remaining  
 266 calculations are based on the day 5 measurements, as follows. It was assumed that  $F_{l.in}$  was  
 267 the same on days 5 and 6 and this was substituted in equation (2) to derive  $F_{l.out}$  on day 5.  
 268 Subsequently, an estimate of the lactate M+1 enrichment on day 5, denoted by  $E_{l.m+1}^*$ , was  
 269 obtained from  $E_{l.m+1}^* = \text{Infusion rate} / (F_{l.in} + \text{Infusion rate})$ , assuming that the infusate was

270 fully labelled. In subsequent calculations,  $E_{1,m+1}^*$  replaced  $E_{1,m+1}$ , so that  $F_{bl}$ ,  $F_{ba}$ ,  $F_{pl}$ ,  $F_{al}$ ,  
271  $F_{a.out}$  and  $F_{a.in}$  could be calculated as before, based on equations (4), (6)-(8). To estimate  
272 the fates of starch, it was assumed that 40% of the lactate came from starch, so that the  
273 lactate M+2 enrichment was assumed to be 0.4 of the starch enrichment. This estimate of  
274 the lactate M+2 enrichments, denoted as  $E_{1,m+2}^*$ , then replaced  $E_{1,m+2}$  in equations (9) – (11)  
275 to provide estimates for  $F_{ls}$ ,  $F_{ps}$  and  $F_{as}$ . Note that  $F_{b.in}$  and  $F_{p.in}$  (equations (3) and (5)  
276 respectively) are unaffected by any of the assumptions.

277 The assumption of  $F_{1.in}$  on day 5 being equal to that on day 6 was supported by data from  
278 donor A at pH 5.5 (0.29 and 0.28  $\mu\text{mol mL}^{-1} \text{h}^{-1}$  respectively). Data from the same volunteer  
279 showed that approximately 40% of the lactate came from starch and this value was applied  
280 to the other volunteers. Based on the model adopted, this assumption should only influence  
281 the calculation of  $F_{ls}$ ,  $F_{ps}$  and  $F_{as}$ . In practice, sensitivity analysis with the proportion of  
282 lactate from starch varied from 1 to 99% only impacted seriously on  $F_{as}$ ,  $F_{ps}$  and  $F_{px}$ , with  
283 the coefficient of variation lower than 36%, except for  $F_{px}$  that showed flows lower than  
284 0.15  $\mu\text{mol mL}^{-1} \text{h}^{-1}$ .

285

## 286 **Statistical analysis**

287 Where SCFA data were replicated the average values were used. The daily SCFA data  
288 from the continuous fermentors were analysed as repeated measures, with volunteer and  
289 time point nested within volunteer as random effects, while time point, pH and their  
290 interaction were taken as fixed effects. The weekly lactate data from the batch culture  
291 incubations were analysed using the same random structure, but with fixed effects now  
292 consisting of time point, pH, substrate and their interactions. To account for dependency on  
293 previous time points, a suitable covariance structure (compound symmetry) was fitted on  
294 the basis of Schwarz's Bayesian information model fit criterion. Quantities (such as carbon  
295 flows, numbers of bacteria) obtained from the day 5 (or day 6) data in the continuous

296 fermentors were analysed as one-way analysis of variance with volunteer as random effect  
297 and pH as fixed effect. Pure culture data on lactate formation and utilization were also  
298 analysed as one-way analysis of variance with pH as fixed effect.  $P < 0.05$  was regarded as  
299 statistically significant. All data were analysed using the MIXED procedure of the SAS  
300 software package, version 9.1 (SAS Inst. Inc., Cary, NC). In addition, the linear  
301 relationships between variables of interest were analysed using the REG procedure of the  
302 SAS software.

303

## 304 **Results**

### 305 **Concentrations of SCFA and lactate over time in continuous flow fermenters**

306 Daily concentrations of SCFA (acetate, propionate, butyrate) and lactate in the single  
307 stage fermentors are presented in Fig. 2. SCFA and lactate concentrations required 3 to 4  
308 days to stabilise in all vessels. Lactate was usually detectable only during the first two days  
309 and reduced to negligible amounts by day 3. For other SCFA (data not shown) succinate  
310 was occasionally detected, albeit at low concentrations, whereas formate had variable  
311 initial values (up to  $4 \text{ mmol L}^{-1}$ ) on day 1 but these decreased to zero by day 3. Volunteer  
312 A at pH 5.5 showed a different pattern to the other volunteers, with butyrate nearly  
313 undetectable ( $< 0.4 \text{ mmol L}^{-1}$ ) by 3 days, while lactate was detectable throughout and  
314 formate was present at approximately  $11 \text{ mmol L}^{-1}$  from day 3 onwards.

315

### 316 **Rates of lactate formation and utilisation**

317 Originally it was expected that lactate concentrations would be above the limits of  
318 detection but, in practice, this only occurred at day 5 for volunteer A at pH 5.5. This  
319 volunteer provided the only direct comparison of metabolism on days 5 and 6, with  
320 endogenous lactate formation similar on both days ( $0.29$  and  $0.28 \text{ } \mu\text{mol mL}^{-1} \text{ h}^{-1}$   
321 respectively). For the other samples, therefore, the various rates of lactate metabolism were

322 calculated based on formation determined on day 6 (Table 1) plus metabolite masses and  
323 enrichments from day 5. These parameters of endogenous lactate metabolism are presented  
324 in Table 2.

325 Lactate formation was consistently greater at the lower pH ( $P < 0.05$ ; Tables 1 and 2)  
326 and a similar trend ( $P = 0.053$ ) was also seen for endogenous lactate utilization (Table 2).  
327 As expected, rates of production and utilization were closely matched to maintain constant  
328 lactate concentrations, even below the limit of detection.

329

### 330 **Carbon flows between starch, lactate and SCFA in continuous fermentors**

331 The continuous infusion of [U-<sup>13</sup>C]starch and [3-<sup>13</sup>C]lactate, together with the bolus  
332 injection of [1,2-<sup>13</sup>C]acetate, [1-<sup>13</sup>C]acetate and [1-<sup>13</sup>C]propionate allowed estimation of  
333 flows (expressed as C<sub>2</sub> units) between lactate and the main SCFA (acetate, propionate,  
334 butyrate; Table 2). Labelled starch also allowed quantification of the flow to lactate.  
335 Carbon flow through the acetate pool ( $F_{a.in}$ ) was considerable (1.7-2.1  $\mu\text{mol mL}^{-1} \text{h}^{-1}$ ), with  
336 most (> 53%) derived from sources other than starch (contribution 16 to 42%) or lactate  
337 (contribution < 14%). Flows from starch to lactate ( $F_{ls}$ ) and from lactate to acetate ( $F_{al}$ )  
338 were greater at the lower pH ( $P < 0.05$ ). Propionate formation (approximately 0.5  $\mu\text{mol}$   
339  $\text{mL}^{-1} \text{h}^{-1}$ ) was independent of pH ( $P > 0.10$ ) and with the majority derived from starch (>  
340 51%  $F_{ps} \cdot F_{p.in}$ ). Butyrate formation ( $F_{b.in}$ ) was similar to propionate formation and was at  
341 least two-fold greater for volunteers C and D than A or B at the lower pH. Most butyrate  
342 derived from lactate (estimated as  $F_{al} \times F_{ba}/F_{a.out}$ ) was via the external acetate pool (>  
343 78%), and involved the action of acetyl-CoA transferase. The exception was volunteer A at  
344 the lower pH where no acetate utilisation or butyrate formation was observed and most  
345 propionate derived from sources (63%) other than starch (21%) or lactate (16%).

346 The proportions of lactate carbon converted to acetate, propionate and butyrate were  
347 also estimated (Table 3). The proportion of lactate converted to propionate was always

348 greater at pH 6 ( $P < 0.05$ ). In contrast, the proportion of lactate metabolised to acetate and  
349 butyrate was independent of pH. The fate of lactate also appeared volunteer-dependent. For  
350 one subject (C) butyrate was the main end product whereas for two other volunteers (A and  
351 D) a substantial amount of the lactate (37-68%) was converted to propionate. The  
352 proportion of butyrate formed from lactate, either directly or via the external acetate pool,  
353 varied between 0-20%.

354

### 355 **FISH quantification of bacteria that produce or utilize lactate**

356 *Bifidobacterium* spp. accounted for 3.8 to 6.1% of the total bacteria present in the fecal  
357 inocula, whereas the populations of the *E. hallii* group were low and more variable (0.04 to  
358 0.61%) and *A. caccae* was below the limit of detection ( $< 0.01\%$ ). By d 5 of inoculation,  
359 total bacterial numbers had increased at least 4-fold (Table 4). By this time, for three  
360 volunteers the bifidobacteria accounted for only 0.3 to 4.2% of total bacteria whereas for  
361 volunteer A the *Bifidobacterium* spp. contribution was 47% at the lower pH (an increase  
362 of  $8.5 \times 10^7 \text{ g}^{-1}$ ). Overall, the  $\log_{10}$  numbers of *Bifidobacterium* spp. only tended to show a  
363 weak relationship with the rate of lactate formation (adjusted  $r^2 = 0.41$ ,  $P = 0.05$ ). The  
364 populations of the *E. hallii* group increased over time by 160-fold but these still accounted  
365 for less than 0.7% of the total bacteria and were not affected by pH.

366

### 367 **Effect of pH on lactate metabolism in batch cultures.**

368 A similar mixture of dietary polysaccharides was used for the batch cultures, in the  
369 presence of either 0 or 35  $\text{mmol L}^{-1}$  DL-lactate. The two pH studied were similar, but not  
370 identical, to the fermentor study (5.9 and 6.5). Over the 24h of batch culture, the pH  
371 remained relatively stable (difference between initial and final pH  $< 0.4$ ).

372 In the absence of added lactate, net lactate formation or utilisation was in balance for  
373 most cultures at both pH. When lactate was added to the initial medium, net disposal was

374 complete in most incubations at pH 6.5 and was always greater ( $P < 0.001$ ) than at pH 5.9  
375 (Table 5). In the absence of lactate, acetate was the main end product, whereas butyrate  
376 accumulated ( $P < 0.001$ ) when lactate was present. The presence of lactate also decreased  
377 net production of acetate ( $P < 0.001$ ) but increased net formation of propionate ( $P <$   
378  $0.001$ ). Furthermore, net production of all three of these SCFA was enhanced at the higher  
379 pH ( $P < 0.005$ ), although for propionate and butyrate this effect was more pronounced with  
380 the mixture plus lactate than the mixture alone (interaction of substrate x pH,  $P < 0.001$ ).  
381 Net lactate utilization was also greater at the higher pH, but again this occurred mainly in  
382 the presence of lactate (interaction of substrate x pH,  $P < 0.001$ ). At the lower pH (5.9) and  
383 with the mixture plus lactate cultures, a linear relationship was observed between net  
384 lactate utilisation and butyrate formation ( $P < 0.001$ ; adjusted  $r^2 = 0.79$ ; Fig. 3).

385

386 Responses varied between volunteers and weeks. For example, net lactate utilisation  
387 and butyrate production were lower for volunteers C and D than A and B, at the lower pH,  
388 and net formation of propionate and butyrate differed between weeks.

389

### 390 **Activity of pure cultures**

391 Estimates of the equi-cell abilities of *B. adolescentis* L2-32 to convert starch to lactate  
392 and *E. hallii* L2-7 to metabolise lactate (to butyrate) are given in Table 6. Both types of  
393 bacteria were more active ( $P < 0.01$ ) at the lower pH. Nonetheless, at both pH the ability of  
394 *E. hallii* L2-7 to dispose of lactate exceeded formation by *B. adolescentis* L2-32 by at least  
395 5-fold.

396

## 397 **Discussion**

### 398 **Kinetics of lactate formation and utilization**



399 Although lactate is a known fermentation product of carbohydrate metabolism within  
400 the colon, the concentrations are usually low or undetectable in faecal samples from  
401 healthy donors (Mcfarlane & Cummings, 1991; Vernia *et al.*, 1988; Duncan *et al.*, 2007).  
402 Thus rapid metabolism must also occur. When lactate accumulates, however, as in patients  
403 with severe ulcerative colitis (Vernia *et al.*, 1988; Hove *et al.*, 1994) then, in the absence of  
404 altered rates of absorption (Umesaki *et al.*, 1979), this must be due to changes in either rate  
405 of formation and(or) disposal. Of the many factors that influence microbial lactate  
406 utilisation and production the most important probably include substrate supply  
407 (Cummings *et al.*, 1989; Duncan *et al.*, 2007), pH (Belenguer *et al.*, 2007; Duncan *et al.*,  
408 2009) and abundance of appropriate bacteria (Roberfroid, 2005). In the present study  
409 substrate supply was fixed and the effect of pH was tested, both on direct metabolism and  
410 via changes in bacterial populations. Use of stable isotopes allowed direct quantification of  
411 lactate production and utilisation as well as the conversion of lactate to propionate or  
412 butyrate, the latter either via butyrate kinase or via the butyryl CoA: acetate CoA  
413 transferase route. Furthermore, co-operative actions between bacteria have been identified  
414 (Wolin *et al.*, 1991; Flint *et al.*, 2007), and including those that produce and utilize lactate  
415 (Duncan *et al.*, 2004b; Belenguer *et al.*, 2006). Therefore, changes in the activity and  
416 population abundances of these bacteria need to be considered alongside the dynamic  
417 quantification of inflows and outflows of specific metabolites. This work suggested that up  
418 to 20% of butyrate production in the mixed community could be derived from lactate  
419 rather than produced directly from carbohydrates.

420 For the fermentor study, the infusion of carbohydrate was equivalent to approximately  
421  $1.7 \mu\text{mol glucose mL}^{-1} \text{h}^{-1}$  with a theoretical maximal lactate formation  $> 3 \mu\text{mol mL}^{-1} \text{h}^{-1}$ .  
422 In practice, observed rates were much lower ( $0.06\text{-}0.34 \mu\text{mol mL}^{-1} \text{h}^{-1}$ ) indicating that only  
423 a small fraction of the carbohydrate (and peptide) substrates were converted to lactate. In  
424 contrast, the capacity to dispose of lactate appears greater, as shown from the rates of

425 disposal observed following a bolus injection of lactate ( $0.36\text{-}0.86\ \mu\text{mol mL}^{-1}\ \text{h}^{-1}$ , data not  
426 shown). A high estimated minimal rate of disposal ( $1.47\ \mu\text{mol mL}^{-1}\ \text{h}^{-1}$ ) was observed for  
427 the batch culture incubations with  $35\ \text{mmol L}^{-1}$  lactate at both pH 5.9 and 6.5. In both the  
428 fermentor and batch approaches, these values represent a capacity for a rapid response and,  
429 therefore, the inherent disposal capacity of the microorganisms involved exceeds the  
430 ability to produce lactate under the substrate conditions employed with these healthy  
431 volunteers. Nonetheless changes in either process can alter lactate concentrations.  
432 Increased lactate formation has also been observed previously in batch cultures at mild to  
433 moderate acidic pH (studied between 5.2 to 6.4; Belenguer *et al.*, 2007). These earlier data  
434 (Belenguer *et al.*, 2007) also showed that lactate utilisation was strongly inhibited at pH  
435 5.2 and this would help explain lactate accumulation in colitis patients, where a similar low  
436 pH occurs (Nugent *et al.*, 2001). At higher pH (5.9), however, the mixed faecal microbiota  
437 were able to rapidly utilise lactate (Belenguer *et al.*, 2007) and thus prevent excessive  
438 accumulation. The current data show that even at a more acidic pH (5.5), but still within  
439 the range reported for the proximal large intestine in healthy people (Bown *et al.*, 1974;  
440 Macfarlane *et al.*, 1992), the capacity for lactate utilization still exceeded lactate formation.  
441 Nonetheless, changes in type and supply of fermentable substrate and environmental  
442 conditions influence both bacterial populations and products of their metabolism. For  
443 example, for stool samples collected weekly over 3 months from the free-living volunteers  
444 in this study only in 29/41 cases was lactate detected (at  $> 1\ \text{mmol per kg faecal water}$ ). All  
445 volunteers had at least five stools with detectable lactate, and the maximum number of  
446 stools with lactate for any one volunteer was eight (out of 12 collections). Thus, all the  
447 volunteers possessed lactate producers.

448

449 **Potential lactate producers and utilizers**

450 Considering lactate producers, *Bifidobacterium* spp. (Florent *et al.*, 1985) are major  
451 starch-utilisers within the human colon (Macfarlane & Englyst, 1986; Leitch *et al.*, 2007).  
452 Furthermore, in pure culture, lactate production by bifidobacteria is stimulated at slightly  
453 acidic pH (Table 6; Belenguer *et al.*, 2006). Therefore, it was expected, based on earlier  
454 observations (Levrat *et al.*, 1991; Silvi *et al.*, 1999; Belenguer *et al.*, 2006), that lactate-  
455 producing bacteria, such as bifidobacteria, and lactate formation would both be increased  
456 in the fermentors at the lower pH with starch as a substrate. Nonetheless, the increase in  
457 bifidobacteria at the lower pH was less, relatively, than the change in lactate production  
458 and raises the question of the importance of the bifidobacteria to lactate metabolism.  
459 Although 41% of the variance in lactate formation within the fermentors could be  
460 explained by the numbers ( $\log_{10}$ ) of *Bifidobacterium* spp. present, the actual numbers of  
461 those bacteria, both in absolute terms and as a percentage of total bacteria, varied between  
462 individuals, as observed previously (Flint *et al.*, 2007). Indeed, when these bacterial  
463 numbers were combined with the rates of lactate production from a starch substrate for  
464 specific *Bifidobacterium* species (Table 6) then this would account for between 2.8-70% of  
465 lactate formation within the fermentors. The largest contribution occurred with volunteer A  
466 at pH 5.5, who had the greatest abundance of *Bifidobacterium* spp. (47% at pH 5.5)  
467 whereas for this volunteer at the higher pH and the other three volunteers at both pH only a  
468 maximum of 21% of lactate formation could be accounted by bifidobacteria. These  
469 observations show that other microorganisms make a very important contribution to  
470 lactate-production. Apart from other lactic acid bacteria such as *Lactobacillus* spp.,  
471 additional bacterial groups known to synthesise lactate are *Collinsella* spp., *E.*  
472 *rectale/Roseburia* spp., *Faecalibacterium prausnitzii*, and *Bacteroides* spp. (Macfarlane &  
473 Gibson, 1991; Barcenilla *et al.*, 2000; Duncan *et al.*, 2002). The latter four groups include  
474 the most abundant bacterial species found within the human intestinal microbiota (Tap *et*

475 *al.*, 2009, Walker *et al.*, 2010) and typically account for >50% of total faecal bacteria (e.g.  
476 Duncan *et al.*, 2007).

477 *E. hallii*, *A. caccae* and the new species *A. coli* (Walker *et al.*, 2010) have been  
478 identified as lactate utilizers (Duncan *et al.*, 2004b) that form butyrate as the end product in  
479 the presence of fermentable polysaccharides (Belenguer *et al.*, 2007). On an equi-cell  
480 basis, the ability of *E. hallii* to metabolise lactate exceeds considerably the capacity for  
481 lactate production by bifidobacteria (Table 6), but there was no relationship between *E.*  
482 *hallii* abundance and total lactate utilisation ( $P > 0.10$ ). Furthermore, the near-maximal rate  
483 of lactate disposal by *E. hallii* (Table 6) when combined with the numbers present in the  
484 fermentors, would only account for 1.2-18.0% of lactate total disposal, with < 4.8% in  
485 most cases. The situation is somewhat different when only lactate converted to butyrate is  
486 considered, however, and where 0-47% could be attributed to the action of *E. hallii*. Thus,  
487 other bacteria must play important roles in the utilization of lactate, including conversion  
488 to butyrate. Interestingly, recent evidence indicates that *A. coli*, that may only utilise D-  
489 lactate, is of similar abundance to *E. hallii* in the human colon (Walker *et al.*, 2010). Other  
490 candidates not detected by the FISH probes used here include *Coprococcus catus* (Louis &  
491 Flint, 2009) and bacteria related to *Megasphaera elsdenii* and *Eubacterium limosum* (Sato  
492 *et al.*, 2008). Involvement of these other bacteria would explain why lactate disposal in the  
493 fermentors (Table 1) was not pH-sensitive and why butyrate was not always the dominant  
494 end-product.

495 In summary, lactate was efficiently used at two physiological pH, 5.5 and 6.0, in  
496 continuous fermentor systems and, in most cases, exceeded rates of lactate production by  
497 species such as *Bifidobacterium*. This ability to dispose of lactate in excess of the amounts  
498 normally produced should be viewed as a beneficial trait for the human colon where  
499 moderate to high accumulation of lactate are usually associated with detrimental responses  
500 (Ewaschuck *et al.*, 2005). While some of the key players have been identified, the relative

501 importance of different bacterial species in lactate formation and disposal within the  
502 microbial community has still to be established.

503

#### 504 **Acknowledgements**

505           The Rowett Research Institute and Biomathematics and Statistics Scotland are  
506 supported by the Scottish Executive Environment and Rural Affairs Department. A.

507 Belenguer received financial support from Spanish Ministry of Education and Science.

508 **References**

- 509 Amann RI, Binder BJ, Olson RJ, Chishom SW, Devereux A & Stahl DA (1990)  
510 Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for  
511 analyzing mixed microbial populations. *Appl Environ Microbiol* **56**: 1919-1925.
- 512 Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS & Flint HJ (2000) Phylogentic  
513 relationships of dominant butyrate producing bacteria from the human gut. *Appl*  
514 *Environ Microbiol* **66**: 1654-1661.
- 515 Belenguer A, Duncan SH, Calder AG, Holtrop G, Louis P, Lobley GE & Flint HJ (2006)  
516 Two routes of metabolic cross-feeding between *Bifidobacterium adolescentis* and  
517 butyrate-producing anaerobes from the human gut. *Appl Environ Microbiol* **72**: 3593-  
518 3599.
- 519 Belenguer A, Duncan SH, Holtrop G, Anderson SE, Lobley GE & Flint HJ (2007) Impact  
520 of pH on lactate formation and utilization by human fecal microbial communities. *Appl*  
521 *Environ Microbiol* **73**: 6526-6533.
- 522 Belenguer A, Duncan SH, Holtrop G, Flint HJ & Lobley GE (2008) Quantitative analysis  
523 of microbial metabolism in the human large intestine. *Curr Nutr Food Sci* **4**: 109-126.
- 524 Bourriaud C, Robins RJ, Martin L, Kozlowski F, Tenailleau E, Cherbut C & Michel C  
525 (2005) Lactate is mainly fermented to butyrate by human intestinal microfloras but  
526 inter-individual variation is evident. *J Appl Microbiol* **99**: 201-212.
- 527 Bown RL, Gibson JA, Sladen GE, Hicks B & Dawson AM (1974) Effects of lactulose and  
528 other laxatives on ileal and colonic pH as measured by radiotelemetry device. *Gut* **15**:  
529 999-1004.
- 530 Cummings JH, Gibson GR & Macfarlane GT (1989) Quantitative estimates of  
531 fermentation in the hind gut of man. *Acta Vet Scand* **86**: 76-82.
- 532 Duncan SH, Hold GL, Harmsen HJM, Stewart CS & Flint HJ. (2002) Growth requirements  
533 and fermentation products of *Fusobacterium prausnitzii*, and a proposal to reclassify it

534 as *Faecalibacterium prausnitzii* gen. nov., comb. nov. *Int J Syst Evol Microbiol* **52**:  
535 2141-2147.

536 Duncan SH, Scott KP, Ramsay AG, Harmsen HJM, Welling GW, Stewart CS & Flint HJ  
537 (2003) Effects of alternative dietary substrates on competition between human colonic  
538 bacteria in an anaerobic fermentor system. *Appl Environ Microbiol* **69**: 1136-1142.

539 Duncan SH, Holtrop G, Lobley GE, Calder G, Stewart CS & Flint HJ (2004a) Contribution  
540 of acetate to butyrate formation by human faecal bacteria. *Br J Nutr* **91**: 915-923.

541 Duncan SH, Louis P & Flint HJ (2004b) Lactate-utilising bacteria, isolated from human  
542 faeces, that produce butyrate as a major fermentation product. *Appl Environ Microbiol*  
543 **70**: 5810-5817.

544 Duncan, SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ & Lobley GE (2007)  
545 Reduced dietary intake of carbohydrate, by obese subjects, results in decreased  
546 concentrations of butyrate and butyrate-producing bacteria in feces. *Appl Environ*  
547 *Micobiol* **73**: 1073-1078.

548 Duncan SH, Louis P, Thomson JM & Flint HJ (2009) The role of pH in determining the  
549 species composition of the human colonic microbiota. *Environ Microbiol* **11**: 2112-  
550 2122.

551 Ewaschuk JB, Naylor JM & Zello GA (2005) D-lactate in human and ruminant  
552 metabolism. *J Nutr* **135**: 1619-1625.

553 Fallinborg J, Christensen LA, Jacobsen BA & Rasmussen SN (1993) Very low  
554 intraluminal colonic pH in patients with active ulcerative colitis. *Dig Dis Sci* **38**: 1989-  
555 1993.

556 Falony G, Vlachou A, Verbrugghe K & De Vuyst L (2006) Cross-feeding between  
557 *Bifidobacterium longum* BB536 and acetate-converting, butyrate-producing colon  
558 bacteria during growth on oligofructose. *Appl Environ Microbiol* **72**: 7835-7841.

559 Flint HJ, Duncan SH, Scott KP & Louis P (2007) Interactions and competition within the  
560 microbial community of the human colon: links between diet and health. *Environ*  
561 *Microbiol* **9**: 1101-1111.

562 Florent C, Flourie B, Leblond A, Rautureau M, Bernier JJ & Rambaud JC (1985) Influence  
563 of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an *in vivo*  
564 study). *J Clin Invest* **75**: 608-613

565 Gill CIR & Rowland IR (2002) Diet and cancer: assessing the risk. *Br J Nutr* **88** (suppl. 1):  
566 S73-S87.

567 Guarner F & Malagelada JR (2003) Gut flora in health and disease. *Lancet* **361**: 512-509.

568 Hamer HM, Jonkers DMAE, Venema K, Vanhoutvin SALW, Troost FJ & Brummer RM  
569 (2008) Review article: The role of butyrate on colonic function. *Aliment Pharmacol*  
570 *Ther* **27**: 104-119.

571 Harmsen HJM, Raangs GC, He T, Degener JE & Welling GW (2002) Extensive set of 16S  
572 rRNA-based probes for detection of bacteria in human faeces. *Appl Environ Microbiol*  
573 **68**: 2982-2990.

574 Hold GL, Pryde SE, Russell VJ, Furrie E & Flint HJ (2002) Assessment of microbial  
575 diversity in human colonic samples by 16S rDNA sequence analysis. *FEMS Microbiol*  
576 *Ecol* **39**: 33-39.

577 Hove H, Norgard Andersen I & Mortensen PB (1994) Fecal DL-lactate concentrations in  
578 100 gastrointestinal patients. *Scand. J Gastroenterol* **29**: 255-259.

579 Jacobasch G., Schmiedl D., Kruschewski M & Schmehl K (1999) Dietary resistant starch  
580 and chronic inflammatory bowel diseases. *Int J Colorect Dis* **14**: 201-211.

581 Langendijk PS, Schut F, Jansen GJ, Raangs GC, Kamphuis GR, Wilkinson MHF &  
582 Welling GW (1995) Quantitative fluorescence *in situ* hybridization of Bifidobacterium  
583 spp. with genus specific 16S rRNA-targeted probes and its application in faecal  
584 samples. *Appl Environ Microbiol* **61**: 3069-3075.



585 Lech K & Brent R (1987) *Current Protocols in Molecular Biology*, (Ausubel FM, Brent R,  
586 Kingston RE, Moore DD, Smith JA, Seidman JG & Struhl K, eds), pp 12.1-12.2. John  
587 Wiley & Sons, New York, USA.

588 Leitch ECM, Walker AW, Duncan SH, Holtrop G & Flint HJ (2007) Selective colonization  
589 of insoluble substrates by human faecal bacteria. *Environ Microbiol* **9**: 667-679.

590 Levrat MA, Remesy C & Demigne C (1991) Very acidic fermentations in the rat cecum  
591 during adaptation to a diet rich in amylase-resistant starch (crude potato starch). *J Nutr*  
592 *Biochem* **2**: 31-36.

593 Louis P & Flint HJ (2009) Diversity, metabolism and microbial ecology of butyrate-  
594 producing bacteria from the human large intestine. *FEMS Microbiol Lett* **294**: 1–8.

595 Louis P, Duncan SH, MacCrae S, Millar J, Jackson MS & Flint HJ (2004) Restricted  
596 distribution of the butyrate kinase pathway among butyrate-producing bacteria from the  
597 human colon. *J Bacteriol* **186**: 2099-2106.

598 Macfarlane GT & Cummings JH (1991) The colonic flora, fermentation and large bowel  
599 digestive function. *The large Intestine: Physiology, Pathophysiology and Disease*,  
600 (Phillips SF, Pemberton JH & Shorter RG, eds),pp 51-92. Raven Press, New York,  
601 USA.

602 Macfarlane GT & Englyst HN (1986) Starch utilization by the human large intestinal  
603 microflora. *J Appl Microbiol* **60**: 195-201.

604 Macfarlane GT & Gibson GR (1991) Co-utilization of polymerized carbon sources by  
605 *Bacteroides ovatus* grown in a two-stage continuous culture system. *Appl Environ*  
606 *Microbiol* **57**: 1-6

607 Macfarlane GT, Hay S & Gibson GR (1989) Influence of mucin on glycosidase, protease  
608 and arylamidase activities of human gut bacteria grown in a 3-stage continuous culture  
609 system. *J Appl Bacteriol* **66**: 407–417.

610 Macfarlane GT, Gibson GR & Cummings JH (1992) Comparison of fermentation reactions  
611 in different regions of the human colon. *J Appl Bacteriol* **72**: 57-64.

612 McIntyre AP, Gibson P & Young GP (1993) Butyrate production from dietary fibre and  
613 protection against large bowel cancer in a gut model. *Gut* **34**: 386–391.

614 Miyazaki K, Martin JC, Marinsek-Logar R & Flint H (1997) Degradation and utilization of  
615 xylans by the rumen anaerobe *Prevotella bryantii* (formerly *P. Ruminicola* subs. *Brevis*  
616 B<sub>14</sub>). *Anaerobe* **3**: 373-381.

617 Morrison DJ, Mackay WG, Edwards CA, Preston T, Dodson B & Weaver LT (2006)  
618 Butyrate production from oligofructose fermentation by the human faecal flora: what is  
619 the contribution of extracellular acetate and lactate?. *Brit J Nutr* **96**: 570-577.

620 Nugent SG, Kumar D, Rampton DS & Evans DF (2001) Intestinal luminal pH in  
621 inflammatory bowel disease: possible determinants and implications for therapy with  
622 aminosalicylates and other drugs. *Gut* **48**: 571-577.

623 Pryde SE, Duncan SH, Hold GL, Stewart CS & Flint HJ (2002) The microbiology of  
624 butyrate formation in the human colon. *FEMS Microbiol Letts* **217**: 133-139.

625 Richardson AJ, Calder AG, Stewart CS & Smith A (1989) Simultaneous determination of  
626 volatile and non-volatile acidic fermentation products of anaerobes by capillary gas  
627 chromatography. *Lett Appl Microbiol* **9**: 5–8.

628 Roberfroid MB (2005) Inulin-type fructans: functional food ingredients. *J Nutr* **137**:  
629 2493S-2502S.

630 Sato T, Matsumoto K, Okumura T, Yokoi W, Naito E, Yoshida Y, Nomoto K, Ito M &  
631 Sawada H (2008) Isolation of lactate-utilizing butyrate-producing bacteria from human  
632 feces and in vivo administration of *Anaerostipes caccae* strain L2 and galacto-  
633 oligosaccharides in a rat model. *FEMS Microbiol Ecol* **66**: 528-536.

634 Silvi S, Rumney CJ, Cresci A & Rowland IR (1999) Resistant starch modifies gut  
635 microflora and microbial metabolism in human flora-associated rats inoculated with  
636 faeces from Italian and UK donors. *J Appl Microbiol* **86**: 521-530.

637 Tap J, Mondot S, Levenez F *et al.* (2009) Towards the human intestinal microbiota  
638 phylogenetic core. *Environ Microbiol* **11**: 2574–2584

639 Tazoe H, Otomo Y, Kaji I *et al.* (2008) Roles of short chain fatty acid receptors, GPR41  
640 and GPR43 on colonic functions. *J Physiol Pharmacol* **59**(suppl 2): 251–262.

641 Umesaki Y, Yajima T, Yokokura T & Mutai M (1979) Effect of organic acid absorption on  
642 bicarbonate transport in rat colon. *Pflügers Arch* **379**: 43-47.

643 Vernia P, Caprilli R, Latella G, Barbetti F, Magliocca FM & Cittadini M (1988) Fecal  
644 lactate and ulcerative colitis. *Gastroenterol* **95**: 1564-1568.

645 Walker AW, Duncan SH, Leitch ECM, Child MW & Flint HJ (2005) pH and peptide  
646 supply can radically alter bacterial populations and short chain fatty acid ratios within  
647 microbial communities from the human colon. *Appl Environ Microbiol* **71**: 3692-3700.

648 Walker AW, Ince J, Duncan SH *et al.* (2010) Dominant and diet-responsive groups of  
649 bacteria within the human colonic microbiota. *ISME J* doi: 10.1038/ISMEJ.2010.118

650 Wolin MJ, Miller TL, Yerry S, Zhang Y, Bank S & Weaver GA (1991) Changes of  
651 fermentation pathways of fecal microbial communities associated with a drug treatment  
652 that increases dietary starch in the human colon. *Appl Environ Microbiol* **65**: 2807-  
653 2812.

654

655

656

657 **Table 1.** Lactate formation ( $F_{l,in}$ ) rates in single stage continuous fermentors inoculated  
658 with faecal suspensions from four different volunteers estimated after a bolus injection of  
659 labelled [ $3\text{-}^{13}\text{C}$ ]-lactate plus DL-lactate at two different pH values (5.5 and 6.0) on day 6 of  
660 study.

	Bolus size <sup>a</sup> ( $\mu\text{mol mL}^{-1}$ )	$F_{l,in}$ ( $\mu\text{mol mL}^{-1} \text{h}^{-1}$ )
Volunteer A		
pH 5.5	2.67	0.28
pH 6.0	2.32	0.07
Volunteer B		
pH 5.5	2.36	0.19
pH 6.0	2.32	0.05
Volunteer C		
pH 5.5	2.25	0.09
pH 6.0	2.56	0.06
Volunteer D		
pH 5.5	2.24	0.34
pH 6.0	2.26	0.12
SED		0.044
<i>P</i> for pH		0.043

661 <sup>a</sup> Includes both DL-lactate plus L[ $^{13}\text{C}$ ]lactate.

662 Data were analysed by analysis of variance, with volunteer as random effect and pH as  
663 fixed effect.

664 SED, standard error of the difference.

665

666 **Table 2.** Estimated carbon flows ( $\mu\text{mol C}_2 \text{ mL}^{-1} \text{ h}^{-1}$ ) between starch, lactate, acetate,  
667 propionate and butyrate estimated from the continuous infusion of labelled [ $^{13}\text{C}_6$ ]-starch  
668 and [ $3\text{-}^{13}\text{C}$ ]-lactate and the bolus injection of [ $1\text{-}^{13}\text{C}$ ]-acetate, [ $1,2\text{-}^{13}\text{C}$ ]-acetate and [ $1\text{-}^{13}\text{C}$ ]-  
669 propionate in single stage continuous fermentors inoculated with faecal suspensions from  
670 four different volunteers at two different pH values (5.5 and 6.0).

	pH 5.5	pH 6.0	SED	<i>P</i> for pH
Lactate production ( $F_{\text{l.in}}$ )	0.23	0.08	0.044	0.044
From starch ( $F_{\text{ls}}$ )	0.09	0.03	0.017	0.043
From other sources ( $F_{\text{lx}}$ )	0.14	0.05	0.027	0.044
Lactate utilization ( $F_{\text{l.out}}$ )	0.25	0.13	0.038	0.053
Acetate production ( $F_{\text{a.in}}$ )	2.13	1.72	0.417	0.401
From starch ( $F_{\text{as}}$ )	0.60	0.38	0.207	0.358
From lactate ( $F_{\text{al}}$ )	0.18	0.06	0.027	0.023
From other sources ( $F_{\text{ax}}$ )	1.34	1.28	0.261	0.843
Acetate utilization ( $F_{\text{a.out}}$ )	1.09	1.08	0.475	0.987
Propionate production ( $F_{\text{p.in}}$ )	0.48	0.50	0.040	0.657
From starch ( $F_{\text{ps}}$ )	0.24	0.33	0.067	0.285
From lactate ( $F_{\text{pl}}$ )	0.07	0.06	0.012	0.669
From other sources ( $F_{\text{px}}$ )	0.17	0.11	0.061	0.438
Butyrate production ( $F_{\text{b.in}}$ )	0.58	0.35	0.200	0.346
From acetate ( $F_{\text{ba}}$ )	0.58	0.35	0.202	0.347
From lactate (via acetate)	0.071	0.024	0.0220	0.120
From lactate (direct; $F_{\text{bl}}$ )	<0.002	<0.003	0.0025	0.677

671 Data were analysed by analysis of variance, with volunteer as random effect and pH as  
672 fixed effect.

673 SED, standard error of the difference.

674

675 **Table 3.** Proportion of the different fates of lactate carbon (acetate, propionate, butyrate)  
 676 and proportion of butyrate derived from lactate in single stage continuous fermentors  
 677 inoculated with faecal suspensions from four different volunteers at two different pH  
 678 values (5.5 and 6.0). The proportions of lactate going to butyrate and of butyrate derived  
 679 from lactate includes both direct and indirect (via extracellular acetate) routes.

Volunteer pH	A		B		C		D		Means		SED	P for pH
	5.5	6.0	5.5	6.0	5.5	6.0	5.5	6.0	5.5	6.0		
Fates of lactate (%)												
To propionate	37.5	50.5	18.2	37.3	4.8	29.0	36.6	68.5	24.2	46.3	4.00	0.012
To butyrate (direct and via acetate)	0.0	13.1	35.2	11.0	66.9	38.6	28.8	19.6	32.7	20.6	9.36	0.285
To acetate <sup>a</sup>	62.5	36.4	46.6	51.7	28.3	32.4	34.6	11.8	43.0	33.1	8.41	0.324
Sources of butyrate (%)												
From lactate (direct and via acetate)	0.0	6.1	20.0	3.8	8.9	12.9	13.4	7.0	10.6	7.5	4.62	0.549

680 <sup>a</sup> Accounts for the lactate-C remaining in acetate, not further metabolized into other

681 products.

682 Data were analysed by analysis of variance, with volunteer as random effect and pH as  
 683 fixed effect.

684 SED, standard error of the difference.

685

686 **Table 4.** Total counts ( $\log_{10}$ ) per ml from inoculation of total bacteria (using the universal  
687 probe Eub338) and the *Bifidobacterium* spp. and *Eubacterium hallii* groups (using the  
688 probes Bif164 and Ehal1469) initially and after 5 days of incubating faecal slurries from  
689 four different volunteers in continuous flow fermenters.

	Total numbers ( $\log_{10}$ )		
	Eub	Bif	Ehal
Volunteer A			
Initial count <sup>a</sup>	7.50	6.13	4.46
pH 5.5	8.27	7.94	5.36
pH 6.0	8.34	6.25	5.82
Volunteer B			
Initial count	7.06	5.69	4.84
pH 5.5	7.91	6.36	5.70
pH 6.0	8.31	6.27	5.84
Volunteer C			
Initial count	7.53	6.11	4.22
pH 5.5	8.28	6.91	5.48
pH 6.0	8.60	6.17	6.43
Volunteer D			
Initial count	7.56	6.35	4.13
pH 5.5	8.43	6.97	5.76
pH 6.0	8.35	6.49	5.74
Means			
Initial count	7.41	6.07	4.41
pH 5.5	8.22	7.04	5.57
pH 6.0	8.40	6.30	5.96
SED	0.111	0.336	0.184
<i>P</i> -value	0.208	0.112	0.128

690 <sup>a</sup> Estimated from faecal counts and taking into account the slurry preparation.

691 SED, standard error of the difference.

692

693 **Table 5.** Net formation or utilization of lactate, acetate, propionate and butyrate (in C<sub>2</sub>  
694 units) in 24 h-incubated batch cultures inoculated with faecal slurries prepared from 4  
695 different healthy volunteers (A, B, C and D) with a mixture of carbohydrates plus 35 mmol  
696 L<sup>-1</sup> lactate and at two pH values (5.9 and 6.7).

697

		Lactate	Acetate	Propionate	Butyrate
Mix	5.9	0.54	9.66	1.35	7.47
	6.5	-0.09	12.6	3.74	6.16
Mix+lactate	5.9	-21.6	2.85	2.80	30.0
	6.5	-33.6	4.91	8.03	38.8
	SED	0.911	0.598	0.319	1.370
	pH	<0.001	<0.001	<0.001	0.007
<i>P</i> -value	substrate	<0.001	<0.001	<0.001	<0.001
	Week	0.73	0.14	0.003	0.019
	Substrate x pH	<0.001	0.49	<0.001	<0.001

698 SED, standard error of the difference.

699



700 **Table 6.** Pure culture data for metabolic rates of lactate formation from starch by  
 701 *Bifidobacterium adolescentis* (L2-32) and utilization of lactate by *Eubacterium hallii* (L2-  
 702 7).

703

pH	Formation $\mu\text{mol } 10^9 \text{ cells}^{-1} \text{ h}^{-1}$	Utilization $\mu\text{mol } 10^9 \text{ cells}^{-1} \text{ h}^{-1}$
5.7	2.36	12.07
6.7	1.23	7.69
SED	0.219	0.844
<i>P</i> for pH	0.007	0.007

704 SED, standard error of the difference

705

706 **Fig. 1.** Tracer and tracee flows. Assumed to be in C<sub>2</sub> units. Black: tracee flow; Orange:  
707 M+2 and tracee flows; Red: M+2, M+1 and tracee flows. All pools also have loss of  
708 material via the effluent, but this has been omitted from the schematic below.

709

710 **Fig. 2.** Time course of the concentrations of acetate (diamond), propionate (triangle),  
711 butyrate (circle) and lactate (square) in single stage-fermentor systems at two different pH  
712 values (5.5 and 6.0) using four different volunteers (A, B, C, and D).

713


714 **Fig. 3.** Relationship between 24h lactate utilisation (mmol L<sup>-1</sup>) and butyrate formation  
715 (mmol L<sup>-1</sup>) in batch cultures inoculated with faecal samples from 4 volunteers (different  
716 symbols for each volunteer), with a mixture of carbohydrates and DL-lactate (35.6 mmol  
717 L<sup>-1</sup>) as substrates at pH 5.9. (P < 0.001 and adjusted r<sup>2</sup> = 0.79)

718

719

720 **Fig. 1.**

721




722

723

724


725  
726 **Fig. 2.**

727 **A.**




728

729 **B.**




730

731 **C.**



732

733 **D.**




734

735

736

737 **Fig. 3.**

738



739

740

741